Topics covered include analytical techniques and methods suitable for API particle sizing and in vitro bioequivalence for nasal drug products as well as preparation methods and a review of case studies. The presentation also provides FDA guidance related to particle size distribution (PSD) and regulatory considerations for PSD testing.
To Request Access: Click Here
Related Posts
Ensuring Container Integrity at Various Temperatures
In the fast-paced world of pharmaceutical development and manufacturing, ensuring...
The Value of Presumptive Screening of Physical Evidence
Authors & ContributorsDavid ExlineCara Plese May 06, 2013 Presumptive tests for blood, seminal fluid, urine, and saliva are fast, relatively inexpensive, and can quickly eliminate a stain from further analysis if the results show the sample is not the fluid originally suspected. Likewise, microscopic analysis of hair is a nondestructive…